Selective growth inhibition of human lung cancer cell lines bearing a surface glycoprotein gp160 by 125I-labeled anti-gp160 monoclonal antibody
- PMID: 3359438
Selective growth inhibition of human lung cancer cell lines bearing a surface glycoprotein gp160 by 125I-labeled anti-gp160 monoclonal antibody
Abstract
Monoclonal antibody 5E8 which is specific for a Mr 160,000 glycoprotein (gp160) on the surface of human lung cancer was radiolabeled with 125I. Radiolabeled 5E8 antibody is shown here to suppress the growth of gp160 positive human lung tumor cell lines in a dose-dependent fashion, but this same radiolabeled antibody does not alter the growth of gp160 negative lung tumor cell lines. Neither the unlabeled 5E8 nor a control radiolabeled monoclonal antibody has any effect upon the growth of gp160 positive tumors. The specificity of radiolabeled antibody mediated tumor killing is further demonstrated by the ability of unlabeled 5E8 to inhibit tumor killing by 125I-5E8. The efficiency with which the labeled tumor specific antibody suppressed tumor colony formation is enhanced by increasing the molar ratio of 125I to 5E8. This ratio could be increased to a level of two without affecting the capacity of the antibody to bind to the cell surface antigen. An attempt to increase the efficiency of tumor killing by the addition of a second antibody subsequent to incubation with 125I-5E8 was unsuccessful. These results indicate that 125I is a viable isotope and gp160 represents an appropriate target for radioimmunotherapy of human lung cancer.
Comment in
-
Correspondence re: Yasuyuki Sugiyama et al., Selective growth inhibition of human lung cancer cell lines bearing a surface glycoprotein gp160 by 125I-labeled anti-gp160 monoclonal antibody.Cancer Res. 1989 Oct 15;49(20):5774-5. Cancer Res. 1989. PMID: 2790790 No abstract available.
Similar articles
-
Membrane-associated glycoprotein (gp 160) identified on human lung tumors by a monoclonal antibody.Cancer Res. 1986 Dec;46(12 Pt 1):6446-51. Cancer Res. 1986. PMID: 3536080
-
Correspondence re: Yasuyuki Sugiyama et al., Selective growth inhibition of human lung cancer cell lines bearing a surface glycoprotein gp160 by 125I-labeled anti-gp160 monoclonal antibody.Cancer Res. 1989 Oct 15;49(20):5774-5. Cancer Res. 1989. PMID: 2790790 No abstract available.
-
Cell surface glycoprotein associated with human lung tumors that is similar to but distinct from the epidermal growth factor receptor.Cancer Res. 1989 Jul 1;49(13):3642-9. Cancer Res. 1989. PMID: 2659165
-
Current status of radioligand antibodies in the treatment of malignancy.Ann Clin Lab Sci. 1988 Jan-Feb;18(1):53-7. Ann Clin Lab Sci. 1988. PMID: 3281561 Review.
-
Generation and characterization of monoclonal antibody B72.3. Experimental and preclinical studies.Targeted Diagn Ther. 1992;6:23-44. Targeted Diagn Ther. 1992. PMID: 1576348 Review. No abstract available.
Cited by
-
The primary structure of the VLA-2/collagen receptor alpha 2 subunit (platelet GPIa): homology to other integrins and the presence of a possible collagen-binding domain.J Cell Biol. 1989 Jul;109(1):397-407. doi: 10.1083/jcb.109.1.397. J Cell Biol. 1989. PMID: 2545729 Free PMC article.
-
Antibody mediated targeting of radioisotopes, drugs and toxins in diagnosis and treatment.Indian J Pediatr. 1990 Jan-Feb;57(1):29-46. doi: 10.1007/BF02722127. Indian J Pediatr. 1990. PMID: 2193879 Review.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Other Literature Sources
Medical